Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

International Collaborative Group for the Study of r-hLH (iCOS-LH)

doi:10.1016/j.fertnstert.2018.01.003

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

International Collaborative Group for the Study of r-hLH (iCOS-LH)

Department of Clinical Medicine

42 Citations (Scopus)

Abstract

Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.

Original language	English
Journal	Fertility and Sterility
Volume	109
Issue number	4
Pages (from-to)	644-664
Number of pages	21
ISSN	0015-0282
DOIs	https://doi.org/10.1016/j.fertnstert.2018.01.003
Publication status	Published - 2018

Keywords

ART
IVF/ICSI
Luteinizing hormone (LH)
ovarian stimulation
recombinant LH

Access to Document

10.1016/j.fertnstert.2018.01.003

http://www.fertstert.org/article/S0015028218300037/pdf

Cite this

@article{32bce188304d42e9bf1e30f0a4a3ae1b,

title = "Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review",

abstract = "Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.",

keywords = "ART, IVF/ICSI, Luteinizing hormone (LH), ovarian stimulation, recombinant LH",

author = "Carlo Alviggi and Alessandro Conforti and Esteves, {Sandro C.} and Andersen, {Claus Yding} and Ernesto Bosch and Klaus B{\"u}hler and Ferraretti, {Anna Pia} and {De Placido}, Giuseppe and Antonio Mollo and Robert Fischer and Peter Humaidan and {International Collaborative Group for the Study of r-hLH (iCOS-LH)}",

year = "2018",

doi = "10.1016/j.fertnstert.2018.01.003",

language = "English",

volume = "109",

pages = "644--664",

journal = "Fertility and Sterility",

issn = "0015-0282",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Recombinant luteinizing hormone supplementation in assisted reproductive technology

T2 - a systematic review

AU - Alviggi, Carlo

AU - Conforti, Alessandro

AU - Esteves, Sandro C.

AU - Andersen, Claus Yding

AU - Bosch, Ernesto

AU - Bühler, Klaus

AU - Ferraretti, Anna Pia

AU - De Placido, Giuseppe

AU - Mollo, Antonio

AU - Fischer, Robert

AU - Humaidan, Peter

AU - International Collaborative Group for the Study of r-hLH (iCOS-LH)

PY - 2018

Y1 - 2018

N2 - Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.

AB - Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.

KW - ART

KW - IVF/ICSI

KW - Luteinizing hormone (LH)

KW - ovarian stimulation

KW - recombinant LH

U2 - 10.1016/j.fertnstert.2018.01.003

DO - 10.1016/j.fertnstert.2018.01.003

M3 - Journal article

C2 - 29653717

AN - SCOPUS:85045076149

SN - 0015-0282

VL - 109

SP - 644

EP - 664

JO - Fertility and Sterility

JF - Fertility and Sterility

IS - 4

ER -

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this